Hong Kong · Delayed Price · Currency is HKD Clover Biopharmaceuticals Statistics
Total Valuation
HKG:2197 has a market cap or net worth of HKD 3.69 billion. The enterprise value is 3.38 billion.
| Market Cap | 3.69B |
| Enterprise Value | 3.38B |
Important Dates
The last earnings date was Wednesday, March 25, 2026.
| Earnings Date | Mar 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:2197 has 1.30 billion shares outstanding. The number of shares has increased by 2.25% in one year.
| Current Share Class | 1.30B |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +2.25% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 20.52% |
| Owned by Institutions (%) | 9.29% |
| Float | 804.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 945.14 |
| PB Ratio | -1.84 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.81 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -686.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.46% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 20.02% |
| Weighted Average Cost of Capital (WACC) | 22.99% |
| Revenue Per Employee | 16,051 |
| Profits Per Employee | -939,212 |
| Employee Count | 243 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1,013.73% in the last 52 weeks. The beta is 3.42, so HKG:2197's price volatility has been higher than the market average.
| Beta (5Y) | 3.42 |
| 52-Week Price Change | +1,013.73% |
| 50-Day Moving Average | 2.24 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 75.58 |
| Average Volume (20 Days) | 4,973,929 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HKG:2197 had revenue of HKD 3.90 million and -228.23 million in losses. Loss per share was -0.18.
| Revenue | 3.90M |
| Gross Profit | 3.05M |
| Operating Income | -288.01M |
| Pretax Income | -228.23M |
| Net Income | -228.23M |
| EBITDA | -256.40M |
| EBIT | -288.01M |
| Loss Per Share | -0.18 |
Balance Sheet
The company has 318.29 million in cash and 11.81 million in debt, with a net cash position of 306.48 million or 0.24 per share.
| Cash & Cash Equivalents | 318.29M |
| Total Debt | 11.81M |
| Net Cash | 306.48M |
| Net Cash Per Share | 0.24 |
| Equity (Book Value) | -2.00B |
| Book Value Per Share | -1.53 |
| Working Capital | -1.57B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 32.16M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 78.17% |
| Operating Margin | -7,384.11% |
| Pretax Margin | -5,851.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:2197 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.25% |
| Shareholder Yield | -2.25% |
| Earnings Yield | -6.19% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |